Exploring Ritlecitinib for Alopecia Areata

EP: 1.Discussing the Pathophysiology of Alopecia Areata

EP: 2.Epidemiology Associated With Alopecia Areata

EP: 3.Common Comorbidities Associated With Alopecia Areata

EP: 4.Hallmark Symptoms Seen With Alopecia Areata

EP: 5.Psychosocial Impact of Alopecia Areata

EP: 6.Diagnosis of Alopecia Areata

EP: 7.Multimodal Care for Patients With Alopecia Areata

EP: 8.Deciding When to Treat Patients With Alopecia Areata

EP: 9.Choosing an Initial Therapy for Alopecia Areata

EP: 10.Adherence to Alopecia Areata Therapies

EP: 11.Adverse Events Associated With Conventional Alopecia Areata Therapies

EP: 12.Exploring Guidelines for Alopecia Areata

EP: 13.Unmet Needs for the Management of Alopecia Areata

EP: 14.Discussing Baricitinib for Alopecia Areata

EP: 15.Highlighting Deuruxolitinib for Alopecia Areata

Now Viewing

EP: 16.Exploring Ritlecitinib for Alopecia Areata

EP: 17.Analyzing the Safety Data of JAK Inhibitors

EP: 18.SALT Scoring for Alopecia Areata

EP: 19.Rapid Therapeutic Effects Seen With a JAK Inhibitor

EP: 20.Future Treatment of Patients With Alopecia Areata

EP: 21.Final Takeaways From the Panelists

Video content above is prompted by the following:

1. Ungar: Ritlecitinib is the first and only treatment approved by the FDA, in 2023, for adolescents (age 12 and older+) with severe AA. What are its distinct properties compared to other JAK inhibitors that contribute to the potential use in adolescents?
   1. How does the introduction of a pediatric treatment option influence your treatment decision?
   2. Where does this leave ritlecitinib in the treatment algorithm for AA
   3. How do you deal with the drug-to-drug interactions associated with this therapy?